Eric Houchin, MD
Family Medicine · Kalamazoo, MINPI 1174522957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,120 of the $59,182 with a category attached, or 86.4%. Alkermes, Inc. accounts for 64.1% of it on its own, with 21 other manufacturers making up the rest. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $187.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$38K
- Indivior Inc.$18K
- Novo Nordisk$2K
- Braeburn Inc.$255
- AstraZeneca$106
- GSK$55
- plus $300 from 16 others
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$51,12086%
- Travel & lodging$2,1394%
- Food & beverage$4,9568%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 51 | $37,960 |
| Indivior Inc. | 45 | $18,422 |
| Novo Nordisk | 164 | $2,084 |
| Braeburn Inc. | 28 | $255 |
| AstraZeneca | 8 | $106 |
| GSK | 3 | $55 |
| AbbVie | 2 | $43 |
| Dexcom, Inc. | 1 | $26 |
| Radius Health, Inc. | 1 | $25 |
| CSL Behring | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Merck | 1 | $18 |
| Orexo US, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Amgen | 1 | $15 |
| Novartis | 1 | $14 |
| Pfizer | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,182 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $166,355 |
| EliquisApixaban | 116 | $106,560 |
| IngrezzaValbenazine Tosylate | 11 | $89,103 |
| FarxigaDapagliflozin Propanediol | 64 | $59,497 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 246 | $52,789 |
| Teriparatide | 13 | $44,204 |
| MounjaroTirzepatide | 36 | $36,451 |
| JanuviaSitagliptin Phosphate | 25 | $30,976 |
| Repatha SureclickEvolocumab | 36 | $26,827 |
| LinzessLinaclotide | 39 | $25,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $24,316 |
| TrulicityDulaglutide | 16 | $23,738 |
| Bydureon BciseExenatide Microspheres | 28 | $22,936 |
| SublocadeBuprenorphine | 11 | $21,716 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $21,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,084 | $166,355147 claims |
| PfizerEliquis, Premarin | $13 | $112,701132 claims |
| AstraZenecaFarxiga | $106 | $59,49764 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $55 | $43,72370 claims |
| AbbVieLinzess, Creon | $43 | $38,17652 claims |
| MerckJanuvia, Belsomra | $18 | $37,34640 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $13 | $34,92553 claims |
| Indivior Inc.Sublocade | $18,422 | $21,71611 claims |
| Johnson & JohnsonXarelto | $15 | $19,89416 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $16,82625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Kalamazoo
- Theresa KordishKalamazoo$87K
- James HuntKalamazoo$17K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.